Cargando…
Cutaneous sarcoidosis due to immune‐checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor
Sarcoidosis is a non‐infective granulomatous disorder of unknown aetiology, with cutaneous involvement affecting up to 30% of patients. Drug‐induced sarcoidosis has been reported secondary to modern melanoma therapies including immune‐checkpoint inhibitors and first generation BRAF inhibitors such a...
Autores principales: | Pham, J. P., Star, P., Wong, S., Damian, D. L., Saw, R. P. M., Whitfeld, M. J., Menzies, A. M., Joshua, A. M., Smith, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060087/ https://www.ncbi.nlm.nih.gov/pubmed/35663773 http://dx.doi.org/10.1002/ski2.71 |
Ejemplares similares
-
Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas
por: Wang, Jinhua, et al.
Publicado: (2014) -
Cutaneous sarcoidosis mimicking pigmented purpuric dermatosis
por: Sauvageau, Andrew P., et al.
Publicado: (2022) -
Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab - a
paradoxical effect? A case report
por: Santos, Guida, et al.
Publicado: (2013) -
Inhibitors of BRAF dimers using an allosteric site
por: Cotto-Rios, Xiomaris M., et al.
Publicado: (2020) -
Cutaneous Manifestations of Sarcoidosis
por: Dogra, Alka, et al.
Publicado: (2012)